Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.

Survival in HPV-associated cancers vary by age, race

14 Nov 2017

The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.

Survival data from 27 population-based US cancer registries were retrieved and used in the analysis. Only cases of invasive cancers that fulfilled the criteria for HPV association were included. The overall and relative 5-year survival rates were calculated for patients diagnosed from 2001 to 2011.

In the study sample of 220,211 patients with HPV-associated cancers, the most common cancer types were oropharyngeal squamous cell carcinomas (SCCs) and cervical carcinomas, observed in 36.4 and 36.1 percent, respectively.

These were followed by anal SCCs (11.8 percent), vulvar SCCs (8.8 percent), penile SCCs (2.8 percent), vaginal SCCs (2.2 percent) and rectal SCCs (1.9 percent).

Five-year age-standardized survival rates were highest for vulvar (66 percent) and anal (65.9 percent) SCCs. In contrast, penile (47.4 percent) and oropharyngeal (51.2 percent) SCCs had the lowest survival rates out of all included cancer types.

Survival for cervical carcinomas, penile SCCs and oropharyngeal SCCs consistently declined with increasing age. On the other hand, those diagnosed with vaginal, vulvar and anal SCCs between the ages of 40 and 49 years had slightly higher survival than those diagnosed at <40 years.

Five-year age-standardized relative survival was higher in Caucasians than African-Americans for cervical carcinomas (64.8 vs 57 percent), penile SCCs (48.4 vs 34.7 percent), anal SCCs (69.3 vs 59.8 percent), rectal SCCs (61.2 vs 45.5 percent) and oropharyngeal SCCs (53.5 vs 32.4 percent).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Roshini Claire Anthony, Yesterday

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.